Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review

Fig. 4

The trend of CEA concentration. The CEA concentration showed a sharp decrease during the cetuximab (600 mg) and the XELOX regimen; the curative effect was even more remarkable (under 10 ng/ml) by using the FOLFIRI and cetuximab regimen (800 mg). The CEA concentration remained relatively stable in the later period

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us